Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.
Identifieur interne : 000A45 ( Istex/Corpus ); précédent : 000A44; suivant : 000A46Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.
Auteurs : D. Deffond ; F. Durif ; M. TournilhacSource :
- Journal of Neurology, Neurosurgery & Psychiatry [ 0022-3050 ] ; 1993-01.
Abstract
The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of "off" phases. The mean duration of SC and SL treatment was 7.7 and 6.8 months respectively. The mean time spent in "off" phase was 55% after SC and 68% after SL treatment. The mean time before turning "on" after an "off" period was 14 minutes after SC and 28 minutes after SL treatment. Two patients developed stomatitis after SL route. SL apomorphine may be helpful in the treatment of motor fluctuations in PD.
Url:
DOI: 10.1136/jnnp.56.1.101
Links to Exploration step
ISTEX:1756F54206E61E7CEF845DBC1A65E661EB3F2BB5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.</title>
<author><name sortKey="Deffond, D" sort="Deffond, D" uniqKey="Deffond D" first="D" last="Deffond">D. Deffond</name>
<affiliation><mods:affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name>
<affiliation><mods:affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Tournilhac, M" sort="Tournilhac, M" uniqKey="Tournilhac M" first="M" last="Tournilhac">M. Tournilhac</name>
<affiliation><mods:affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</mods:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:1756F54206E61E7CEF845DBC1A65E661EB3F2BB5</idno>
<date when="1993" year="1993">1993</date>
<idno type="doi">10.1136/jnnp.56.1.101</idno>
<idno type="url">https://api.istex.fr/document/1756F54206E61E7CEF845DBC1A65E661EB3F2BB5/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000A45</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000A45</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.</title>
<author><name sortKey="Deffond, D" sort="Deffond, D" uniqKey="Deffond D" first="D" last="Deffond">D. Deffond</name>
<affiliation><mods:affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Durif, F" sort="Durif, F" uniqKey="Durif F" first="F" last="Durif">F. Durif</name>
<affiliation><mods:affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</mods:affiliation>
</affiliation>
</author>
<author><name sortKey="Tournilhac, M" sort="Tournilhac, M" uniqKey="Tournilhac M" first="M" last="Tournilhac">M. Tournilhac</name>
<affiliation><mods:affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</mods:affiliation>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title>
<title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title>
<idno type="ISSN">0022-3050</idno>
<idno type="eISSN">1468-330X</idno>
<imprint><publisher>BMJ Publishing Group Ltd</publisher>
<date type="published" when="1993-01">1993-01</date>
<biblScope unit="volume">56</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="101">101</biblScope>
</imprint>
<idno type="ISSN">0022-3050</idno>
</series>
<idno type="istex">1756F54206E61E7CEF845DBC1A65E661EB3F2BB5</idno>
<idno type="DOI">10.1136/jnnp.56.1.101</idno>
<idno type="href">jnnp-56-101.pdf</idno>
<idno type="PMID">8429309</idno>
<idno type="local">jnnp;56/1/101</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0022-3050</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of "off" phases. The mean duration of SC and SL treatment was 7.7 and 6.8 months respectively. The mean time spent in "off" phase was 55% after SC and 68% after SL treatment. The mean time before turning "on" after an "off" period was 14 minutes after SC and 28 minutes after SL treatment. Two patients developed stomatitis after SL route. SL apomorphine may be helpful in the treatment of motor fluctuations in PD.</div>
</front>
</TEI>
<istex><corpusName>bmj</corpusName>
<author><json:item><name>D Deffond</name>
<affiliations><json:string>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</json:string>
</affiliations>
</json:item>
<json:item><name>F Durif</name>
<affiliations><json:string>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</json:string>
</affiliations>
</json:item>
<json:item><name>M Tournilhac</name>
<affiliations><json:string>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</json:string>
</affiliations>
</json:item>
</author>
<language><json:string>eng</json:string>
</language>
<originalGenre><json:string>research-article</json:string>
</originalGenre>
<abstract>The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of "off" phases. The mean duration of SC and SL treatment was 7.7 and 6.8 months respectively. The mean time spent in "off" phase was 55% after SC and 68% after SL treatment. The mean time before turning "on" after an "off" period was 14 minutes after SC and 28 minutes after SL treatment. Two patients developed stomatitis after SL route. SL apomorphine may be helpful in the treatment of motor fluctuations in PD.</abstract>
<qualityIndicators><score>5.081</score>
<pdfVersion>1.3</pdfVersion>
<pdfPageSize>595.27 x 841.89 pts (A4)</pdfPageSize>
<refBibsNative>false</refBibsNative>
<keywordCount>0</keywordCount>
<abstractCharCount>619</abstractCharCount>
<pdfWordCount>1857</pdfWordCount>
<pdfCharCount>11816</pdfCharCount>
<pdfPageCount>3</pdfPageCount>
<abstractWordCount>102</abstractWordCount>
</qualityIndicators>
<title>Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.</title>
<pmid><json:string>8429309</json:string>
</pmid>
<refBibs><json:item><host><author></author>
<title>Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes</title>
</host>
</json:item>
<json:item><author><json:item><name>Jp Frankel</name>
</json:item>
<json:item><name>Aj Lees</name>
</json:item>
<json:item><name>Pa Kempster</name>
</json:item>
<json:item><name>Gm Stern</name>
</json:item>
</author>
<host><volume>53</volume>
<pages><last>101</last>
<first>96</first>
</pages>
<author></author>
<title>J Neurol Neurosurg Psychiatry</title>
<publicationDate>1990</publicationDate>
</host>
<title>Subcutaneous apomorphine in the treatment of Parkinson's disease</title>
<publicationDate>1990</publicationDate>
</json:item>
<json:item><author><json:item><name>W Poewe</name>
</json:item>
<json:item><name>B Kleedorfer</name>
</json:item>
<json:item><name>F Gerstenbrand</name>
</json:item>
<json:item><name>W Oertel</name>
</json:item>
</author>
<host><volume>i</volume>
<pages><first>943</first>
</pages>
<author></author>
<title>Lancet</title>
<publicationDate>1988</publicationDate>
</host>
<title>Subcutaneous apomorphine in Parkinson's disease</title>
<publicationDate>1988</publicationDate>
</json:item>
<json:item><author><json:item><name>P Pollak</name>
</json:item>
<json:item><name>As Champay</name>
</json:item>
<json:item><name>Jm Gaio</name>
</json:item>
<json:item><name>M Hommel</name>
</json:item>
<json:item><name>Al Benabid</name>
</json:item>
<json:item><name>J Perret</name>
</json:item>
</author>
<host><volume>146</volume>
<pages><last>22</last>
<first>116</first>
</pages>
<author></author>
<title>Rev Neurol</title>
<publicationDate>1990</publicationDate>
</host>
<title>Administration sous-cutanee d'apomorphine dans les fluctuations motrices de la maladie de Parkinson</title>
<publicationDate>1990</publicationDate>
</json:item>
<json:item><author><json:item><name>Cmh Stibe</name>
</json:item>
<json:item><name>Pa Kempster</name>
</json:item>
<json:item><name>Aj Lees</name>
</json:item>
<json:item><name>Gm Stern</name>
</json:item>
</author>
<host><volume>i</volume>
<pages><last>6</last>
<first>403</first>
</pages>
<author></author>
<title>Lancet</title>
<publicationDate>1988</publicationDate>
</host>
<title>Subcutaneous apomorphine in parkinsonian on-off fluctuations</title>
<publicationDate>1988</publicationDate>
</json:item>
<json:item><author><json:item><name>F Durif</name>
</json:item>
<json:item><name>D Deffond</name>
</json:item>
<json:item><name>M Tournilhac</name>
</json:item>
</author>
<host><volume>53</volume>
<pages><last>105</last>
<first>1</first>
</pages>
<author></author>
<title>J7 N'eurol Neurosurg Psychiatry</title>
<publicationDate>1990</publicationDate>
</host>
<title>Efficacv of sublingual apomorphine in Parkinson's disease</title>
<publicationDate>1990</publicationDate>
</json:item>
<json:item><author><json:item><name>St Gancher</name>
</json:item>
<json:item><name>Jg Nutt</name>
</json:item>
<json:item><name>Wr Woodward</name>
</json:item>
</author>
<host><volume>1996</volume>
<pages><last>6</last>
<first>212</first>
</pages>
<issue>1</issue>
<author></author>
<title>Mov Dis</title>
</host>
<title>Absorption of apomorphine by various routes in parkinsonism</title>
</json:item>
<json:item><author><json:item><name>Aj Lees</name>
</json:item>
<json:item><name>Jl Montastruc</name>
</json:item>
<json:item><name>N Turjanski</name>
</json:item>
<json:item><name>Rascol,0 Kleedorfer</name>
</json:item>
<json:item><name>B </name>
</json:item>
<json:item><name>Saint Paul</name>
</json:item>
<json:item><name>H Stern</name>
</json:item>
<json:item><name>Gm Rascol</name>
</json:item>
<json:item><name>A </name>
</json:item>
</author>
<host><volume>52</volume>
<pages><first>1440</first>
</pages>
<author></author>
<title>J Neurol Neurosurg Psychiatry</title>
<publicationDate>1989</publicationDate>
</host>
<title>Sublingual apomorphine and Parkinson's disease</title>
<publicationDate>1989</publicationDate>
</json:item>
<json:item><author><json:item><name>Aj Hughes</name>
</json:item>
<json:item><name>R Webster</name>
</json:item>
<json:item><name>M Bovington</name>
</json:item>
<json:item><name>Aj Lees</name>
</json:item>
<json:item><name>Gm Stern</name>
</json:item>
</author>
<host><volume>14</volume>
<pages><last>61</last>
<first>556</first>
</pages>
<author></author>
<title>Clin Neuropharmacol</title>
<publicationDate>1991</publicationDate>
</host>
<title>Sublingual apomorphine in the treatment of Parkinson's disease complicated by motor fluctuations</title>
<publicationDate>1991</publicationDate>
</json:item>
<json:item><author><json:item><name>S Fahn</name>
</json:item>
<json:item><name>Rll Elton</name>
</json:item>
<json:item><name> Members</name>
</json:item>
<json:item><name>Updrs The</name>
</json:item>
</author>
<host><pages><last>63</last>
<first>153</first>
</pages>
<author></author>
<title>Recent developments in Parkinson's disease and appendices</title>
<publicationDate>1987</publicationDate>
</host>
<title>Unified Parkinson's Disease Rating Scale</title>
<publicationDate>1987</publicationDate>
</json:item>
<json:item><author><json:item><name>F Durif</name>
</json:item>
<json:item><name>E Jeanneau</name>
</json:item>
<json:item><name>F Serre-Debeauvais</name>
</json:item>
<json:item><name>D Deffond</name>
</json:item>
<json:item><name>A Eschalier</name>
</json:item>
<json:item><name>M Tournilhac</name>
</json:item>
</author>
<host><volume>19941</volume>
<pages><last>94</last>
<first>493</first>
</pages>
<issue>1</issue>
<author></author>
<title>Eur 7 Clin Pharmacol</title>
</host>
<title>Relationship between plasma concentration of sublingual apomorphine and motor score in Parkinson's disease</title>
</json:item>
<json:item><author><json:item><name>Jl Montastruc</name>
</json:item>
<json:item><name>Rascol,0 Senard</name>
</json:item>
<json:item><name>Jm </name>
</json:item>
</author>
<host><volume>14</volume>
<pages><last>37</last>
<first>432</first>
</pages>
<author></author>
<title>Clin Neuropharmacol</title>
<publicationDate>1991</publicationDate>
</host>
<title>Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study</title>
<publicationDate>1991</publicationDate>
</json:item>
<json:item><author><json:item><name>Gc Cotzias</name>
</json:item>
<json:item><name>Ps Papavasiliou</name>
</json:item>
<json:item><name>Es Tolosa</name>
</json:item>
<json:item><name>Js Mendez</name>
</json:item>
</author>
<host><author></author>
<title>Bell- Midura MM</title>
</host>
</json:item>
<json:item><author><json:item><name>L Frey</name>
</json:item>
</author>
<host><volume>40</volume>
<pages><last>104</last>
<first>97</first>
</pages>
<author></author>
<title>Revue Neurologique</title>
<publicationDate>1923</publicationDate>
</host>
<title>Le syndrome du nerf auriculo-temporal</title>
<publicationDate>1923</publicationDate>
</json:item>
<json:item><author><json:item><name>Jms Pearce</name>
</json:item>
</author>
<host><volume>18</volume>
<pages><last>12</last>
<first>409</first>
</pages>
<author></author>
<title>British J Clinical Practice</title>
<publicationDate>1964</publicationDate>
</host>
<title>Abnormal facial sweating</title>
<publicationDate>1964</publicationDate>
</json:item>
<json:item><author><json:item><name>Mj Burton</name>
</json:item>
<json:item><name>M Brochwicz-Lewinski</name>
</json:item>
</author>
<host><volume>84</volume>
<pages><last>20</last>
<first>619</first>
</pages>
<author></author>
<title>J Roy Soc Med</title>
<publicationDate>1991</publicationDate>
</host>
<title>Lucja Frey and the auriculotemporal nerve syndrome</title>
<publicationDate>1991</publicationDate>
</json:item>
<json:item><host><pages><last>90</last>
<first>189</first>
</pages>
<author><json:item><name>Ej Herman</name>
</json:item>
<json:item><name> Historia Neurologii</name>
</json:item>
<json:item><name> Polshkiej</name>
</json:item>
</author>
<title>Wroclaw: Zaklad Narodowy Imienia Ossoliskich Wydawnicto Polskiej Akademii Nauk</title>
<publicationDate>1975</publicationDate>
</host>
</json:item>
<json:item><host><pages><last>9</last>
<first>431</first>
</pages>
<author><json:item><name>M Duphenix</name>
</json:item>
</author>
<title>Observations sur les fistules du canal salivaire de Stenson. Memoires de l'Academie Royale de Chirugie 1757</title>
</host>
</json:item>
</refBibs>
<genre><json:string>research-article</json:string>
</genre>
<host><volume>56</volume>
<pages><first>101</first>
</pages>
<issn><json:string>0022-3050</json:string>
</issn>
<issue>1</issue>
<genre><json:string>journal</json:string>
</genre>
<language><json:string>unknown</json:string>
</language>
<eissn><json:string>1468-330X</json:string>
</eissn>
<title>Journal of Neurology, Neurosurgery & Psychiatry</title>
</host>
<categories><wos><json:string>social science</json:string>
<json:string>psychiatry</json:string>
<json:string>science</json:string>
<json:string>surgery</json:string>
<json:string>clinical neurology</json:string>
</wos>
<scienceMetrix><json:string>health sciences</json:string>
<json:string>clinical medicine</json:string>
<json:string>neurology & neurosurgery</json:string>
</scienceMetrix>
</categories>
<publicationDate>1993</publicationDate>
<copyrightDate>1993</copyrightDate>
<doi><json:string>10.1136/jnnp.56.1.101</json:string>
</doi>
<id>1756F54206E61E7CEF845DBC1A65E661EB3F2BB5</id>
<score>0.35086384</score>
<fulltext><json:item><extension>pdf</extension>
<original>true</original>
<mimetype>application/pdf</mimetype>
<uri>https://api.istex.fr/document/1756F54206E61E7CEF845DBC1A65E661EB3F2BB5/fulltext/pdf</uri>
</json:item>
<json:item><extension>zip</extension>
<original>false</original>
<mimetype>application/zip</mimetype>
<uri>https://api.istex.fr/document/1756F54206E61E7CEF845DBC1A65E661EB3F2BB5/fulltext/zip</uri>
</json:item>
<istex:fulltextTEI uri="https://api.istex.fr/document/1756F54206E61E7CEF845DBC1A65E661EB3F2BB5/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.</title>
<respStmt><resp>Références bibliographiques récupérées via GROBID</resp>
<name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name>
</respStmt>
</titleStmt>
<publicationStmt><authority>ISTEX</authority>
<publisher>BMJ Publishing Group Ltd</publisher>
<availability><p>BMJ</p>
</availability>
<date>1993-01-01</date>
</publicationStmt>
<sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.</title>
<author xml:id="author-1"><persName><forename type="first">D</forename>
<surname>Deffond</surname>
</persName>
<affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</affiliation>
</author>
<author xml:id="author-2"><persName><forename type="first">F</forename>
<surname>Durif</surname>
</persName>
<affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</affiliation>
</author>
<author xml:id="author-3"><persName><forename type="first">M</forename>
<surname>Tournilhac</surname>
</persName>
<affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</affiliation>
</author>
</analytic>
<monogr><title level="j">Journal of Neurology, Neurosurgery & Psychiatry</title>
<title level="j" type="abbrev">J Neurol Neurosurg Psychiatry</title>
<idno type="pISSN">0022-3050</idno>
<idno type="eISSN">1468-330X</idno>
<imprint><publisher>BMJ Publishing Group Ltd</publisher>
<date type="published" when="1993-01"></date>
<biblScope unit="volume">56</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="101">101</biblScope>
</imprint>
</monogr>
<idno type="istex">1756F54206E61E7CEF845DBC1A65E661EB3F2BB5</idno>
<idno type="DOI">10.1136/jnnp.56.1.101</idno>
<idno type="href">jnnp-56-101.pdf</idno>
<idno type="PMID">8429309</idno>
<idno type="local">jnnp;56/1/101</idno>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><creation><date>1993-01-01</date>
</creation>
<langUsage><language ident="en">en</language>
</langUsage>
<abstract xml:lang="en"><p>The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of "off" phases. The mean duration of SC and SL treatment was 7.7 and 6.8 months respectively. The mean time spent in "off" phase was 55% after SC and 68% after SL treatment. The mean time before turning "on" after an "off" period was 14 minutes after SC and 28 minutes after SL treatment. Two patients developed stomatitis after SL route. SL apomorphine may be helpful in the treatment of motor fluctuations in PD.</p>
</abstract>
</profileDesc>
<revisionDesc><change when="1993-01-01">Created</change>
<change when="1993-01">Published</change>
<change xml:id="refBibs-istex" who="#ISTEX-API" when="2017-01-19">References added</change>
</revisionDesc>
</teiHeader>
</istex:fulltextTEI>
<json:item><extension>txt</extension>
<original>false</original>
<mimetype>text/plain</mimetype>
<uri>https://api.istex.fr/document/1756F54206E61E7CEF845DBC1A65E661EB3F2BB5/fulltext/txt</uri>
</json:item>
</fulltext>
<metadata><istex:metadataXml wicri:clean="corpus bmj" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration>
<istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType>
<istex:document><article article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="hwp">jnnp</journal-id>
<journal-id journal-id-type="nlm-ta">J Neurol Neurosurg Psychiatry</journal-id>
<journal-title>Journal of Neurology, Neurosurgery & Psychiatry</journal-title>
<abbrev-journal-title abbrev-type="publisher">J Neurol Neurosurg Psychiatry</abbrev-journal-title>
<issn pub-type="ppub">0022-3050</issn>
<issn pub-type="epub">1468-330X</issn>
<publisher><publisher-name>BMJ Publishing Group Ltd</publisher-name>
</publisher>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">8429309</article-id>
<article-id pub-id-type="other">jnnp;56/1/101</article-id>
<article-id pub-id-type="doi">10.1136/jnnp.56.1.101</article-id>
<article-id pub-id-type="other">101</article-id>
<article-id pub-id-type="other">jnnp.56.1.101</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.</article-title>
</title-group>
<contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Deffond</surname>
<given-names>D</given-names>
</name>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Durif</surname>
<given-names>F</given-names>
</name>
</contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Tournilhac</surname>
<given-names>M</given-names>
</name>
</contrib>
</contrib-group>
<aff>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</aff>
<pub-date pub-type="ppub"><month>1</month>
<year>1993</year>
</pub-date>
<pub-date pub-type="epub"><day>1</day>
<month>1</month>
<year>1993</year>
</pub-date>
<volume>56</volume>
<volume-id pub-id-type="other">56</volume-id>
<volume-id pub-id-type="other">56</volume-id>
<issue>1</issue>
<issue-id pub-id-type="other">jnnp;56/1</issue-id>
<issue-id pub-id-type="other">1</issue-id>
<issue-id pub-id-type="other">56/1</issue-id>
<fpage>101</fpage>
<self-uri content-type="pdf" xlink:role="full-text" xlink:href="jnnp-56-101.pdf"></self-uri>
<abstract><p>The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of "off" phases. The mean duration of SC and SL treatment was 7.7 and 6.8 months respectively. The mean time spent in "off" phase was 55% after SC and 68% after SL treatment. The mean time before turning "on" after an "off" period was 14 minutes after SC and 28 minutes after SL treatment. Two patients developed stomatitis after SL route. SL apomorphine may be helpful in the treatment of motor fluctuations in PD.</p>
</abstract>
</article-meta>
</front>
</article>
</istex:document>
</istex:metadataXml>
<mods version="3.6"><titleInfo lang="en"><title>Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.</title>
</titleInfo>
<titleInfo type="alternative" lang="en" contentType="CDATA"><title>Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes.</title>
</titleInfo>
<name type="personal"><namePart type="given">D</namePart>
<namePart type="family">Deffond</namePart>
<affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">F</namePart>
<namePart type="family">Durif</namePart>
<affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<name type="personal"><namePart type="given">M</namePart>
<namePart type="family">Tournilhac</namePart>
<affiliation>Clinique Neurologique, Hôpital Fontmaure, Chamalieres, France.</affiliation>
<role><roleTerm type="text">author</roleTerm>
</role>
</name>
<typeOfResource>text</typeOfResource>
<genre type="research-article" displayLabel="research-article"></genre>
<originInfo><publisher>BMJ Publishing Group Ltd</publisher>
<dateIssued encoding="w3cdtf">1993-01</dateIssued>
<dateCreated encoding="w3cdtf">1993-01-01</dateCreated>
<copyrightDate encoding="w3cdtf">1993</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
<languageTerm type="code" authority="rfc3066">en</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
</physicalDescription>
<abstract lang="en">The efficacy of two routes of apomorphine, subcutaneous (SC) and sublingual (SL), successively administered in 7 Parkinsonian patients with motor fluctuations, was compared in reducing the daily duration of "off" phases. The mean duration of SC and SL treatment was 7.7 and 6.8 months respectively. The mean time spent in "off" phase was 55% after SC and 68% after SL treatment. The mean time before turning "on" after an "off" period was 14 minutes after SC and 28 minutes after SL treatment. Two patients developed stomatitis after SL route. SL apomorphine may be helpful in the treatment of motor fluctuations in PD.</abstract>
<relatedItem type="host"><titleInfo><title>Journal of Neurology, Neurosurgery & Psychiatry</title>
</titleInfo>
<titleInfo type="abbreviated"><title>J Neurol Neurosurg Psychiatry</title>
</titleInfo>
<genre type="journal">journal</genre>
<identifier type="ISSN">0022-3050</identifier>
<identifier type="eISSN">1468-330X</identifier>
<identifier type="PublisherID-hwp">jnnp</identifier>
<identifier type="PublisherID-nlm-ta">J Neurol Neurosurg Psychiatry</identifier>
<part><date>1993</date>
<detail type="volume"><caption>vol.</caption>
<number>56</number>
</detail>
<detail type="issue"><caption>no.</caption>
<number>1</number>
</detail>
<extent unit="pages"><start>101</start>
</extent>
</part>
</relatedItem>
<identifier type="istex">1756F54206E61E7CEF845DBC1A65E661EB3F2BB5</identifier>
<identifier type="DOI">10.1136/jnnp.56.1.101</identifier>
<identifier type="href">jnnp-56-101.pdf</identifier>
<identifier type="PMID">8429309</identifier>
<identifier type="local">jnnp;56/1/101</identifier>
<recordInfo><recordContentSource>BMJ</recordContentSource>
</recordInfo>
</mods>
</metadata>
<serie></serie>
</istex>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000A45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= Istex |étape= Corpus |type= RBID |clé= ISTEX:1756F54206E61E7CEF845DBC1A65E661EB3F2BB5 |texte= Apomorphine in treatment of Parkinson's disease: comparison between subcutaneous and sublingual routes. }}
![]() | This area was generated with Dilib version V0.6.29. | ![]() |